2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis

Felson D, Smolen J, Wells G, Zhang B, van Tuyl L, Funovits J . American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011; 63(3):573-86. PMC: 3115717. DOI: 10.1002/art.30129. View

Emery P, Breedveld F, Hall S, Durez P, Chang D, Robertson D . Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008; 372(9636):375-82. DOI: 10.1016/S0140-6736(08)61000-4. View

Shekelle P . The appropriateness method. Med Decis Making. 2004; 24(2):228-31. DOI: 10.1177/0272989X04264212. View

Kimel M, Cifaldi M, Chen N, Revicki D . Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2007; 35(2):206-15. View

Aletaha D, Ward M, Machold K, Nell V, Stamm T, Smolen J . Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005; 52(9):2625-36. DOI: 10.1002/art.21235. View

Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A . Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003; 62(2):120-6. PMC: 1754441. DOI: 10.1136/ard.62.2.120. View

Agrawal S, Misra R, Aggarwal A . Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2006; 26(2):201-4. DOI: 10.1007/s10067-006-0275-5. View

Pincus T . The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis. Clin Exp Rheumatol. 2005; 23(5 Suppl 39):S109-13. View

Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G . Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2005; 65(4):453-8. PMC: 1798112. DOI: 10.1136/ard.2005.041376. View

10.

Smolen J, Landewe R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6):964-75. PMC: 2935329. DOI: 10.1136/ard.2009.126532. View

11.

Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343(22):1586-93. DOI: 10.1056/NEJM200011303432201. View

12.

HURST J, Morris D, Alexander R . The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol. 1999; 22(6):385-90. PMC: 6656155. DOI: 10.1002/clc.4960220604. View

13.

Singh J, Beg S, Lopez-Olivo M . Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; (7):CD008331. DOI: 10.1002/14651858.CD008331.pub2. View

14.

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

15.

van der Kooij S, le Cessie S, Goekoop-Ruiterman Y, de Vries-Bouwstra J, van Zeben D, Kerstens P . Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2008; 68(7):1153-8. DOI: 10.1136/ard.2008.093294. View

16.

Ruiz Garcia V, Jobanputra P, Burls A, Cabello J, Galvez Munoz J, Saiz Cuenca E . Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2011; (2):CD007649. DOI: 10.1002/14651858.CD007649.pub2. View

17.

Smolen J, Breedveld F, Schiff M, Kalden J, Emery P, Eberl G . A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003; 42(2):244-57. DOI: 10.1093/rheumatology/keg072. View

18.

Bresnihan B . Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol Suppl. 2002; 65:39-43. View

19.

Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V . Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003; 62(5):427-30. PMC: 1754544. DOI: 10.1136/ard.62.5.427. View

20.

Singh J, Christensen R, Wells G, Suarez-Almazor M, Buchbinder R, Lopez-Olivo M . Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009; (4):CD007848. PMC: 10636593. DOI: 10.1002/14651858.CD007848.pub2. View